On behalf of the Organising and Scientific Committees, we are honoured to welcome you to the 8^th International Cerebral Amyloid Angiopathy (CAA) Conference, Perth, Western Australia. 

The past 2 years have brought many challenges to high level research due to the COVID-19 pandemic, with physical distancing and other difficulties including travel restrictions, limited access to research facilities and participants, and an overall struggle to conduct research in these challenging times. We are proud to report that, even with the constraints imposed by the pandemic, this year’s program will present the highest quality research and knowledge on the diagnosis, prevention and treatment of CAA and continues to maintain the momentum that started the International CAA Conference about 12 years ago. 

Ongoing high-quality CAA research across the globe has expanded our understanding of the clinical, aetiological, and pathological trajectory of this condition. Current advances involving biofluid markers as well as clinical and radiological features are transforming the perspectives for future research directions in CAA and increasing therapeutic options for clinical trials. 

Attend the conference to share your own findings, learn more about the latest research and techniques, and gather information to help your clinical practice in treatment and diagnosis. The conference will connect internationally renowned scientists and clinicians from all CAA research pathways – bench to bedside.

The 2022 Conference is the first to be held outside North America and Europe. Perth, Western Australia, was selected as a city known for its close involvement in CAA research and its endless sunshine and pristine beaches. Perth is accessed via Perth International Airport, with direct connections to London, Tokyo, Johannesburg, and Dubai, among many others.

We look forward to seeing you in Perth, Western Australia, on November 3-5, 2022.